Instagram Outage Disrupts Thousands of U.S. Users 
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine 
Trump Allegedly Sought Airport, Penn Station Renaming in Exchange for Hudson River Tunnel Funding 
U.S. to Begin Paying UN Dues as Financial Crisis Spurs Push for Reforms 
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million 
Iran–U.S. Nuclear Talks in Oman Face Major Hurdles Amid Rising Regional Tensions 
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports 
South Korea Assures U.S. on Trade Deal Commitments Amid Tariff Concerns 
Nvidia Nears $20 Billion OpenAI Investment as AI Funding Race Intensifies 
Pentagon Ends Military Education Programs With Harvard University 
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off 
Trump Says “Very Good Talks” Underway on Russia-Ukraine War as Peace Efforts Continue 
Trump Rejects Putin’s New START Extension Offer, Raising Fears of a New Nuclear Arms Race 
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate 
Trump Signs Executive Order Threatening 25% Tariffs on Countries Trading With Iran 
TrumpRx.gov Highlights GLP-1 Drug Discounts but Offers Limited Savings for Most Americans 
Pfizer and U.S. President Donald Trump announced a landmark agreement on Tuesday, under which the pharmaceutical giant will lower prescription drug prices in the Medicaid program to levels comparable to other developed nations. In exchange, Pfizer secured tariff relief on its products. The deal positions Pfizer as the first drugmaker to comply with Trump’s push to align U.S. drug prices with global standards.
Under the agreement, Pfizer committed to applying most-favored-nation pricing on all new drugs launched in the U.S. from 2026. Trump also introduced TrumpRx, a White House-backed direct-to-consumer drug platform set to launch the same year, allowing Americans to access discounted medications directly. This move follows Trump’s earlier threats to impose a 100% tariff on branded pharmaceutical imports unless manufacturers boosted U.S. production.
Pfizer will invest $70 billion in domestic research, development, and manufacturing, securing a three-year grace period from the planned tariffs. CEO Albert Bourla confirmed the company would relocate more production to the U.S., where it currently operates nine manufacturing facilities. The deal covers a range of therapies, including Xeljanz, Zavzpret, Eucrisa, and Duavee, with discounts averaging 50% and in some cases reaching up to 85%.
The announcement boosted investor confidence, sending Pfizer shares up more than 6% and lifting other drugmakers like Eli Lilly, Merck, and Amgen. Analysts noted that limiting concessions to Medicaid minimized the industry’s financial impact, since Medicaid drug spending—around $80 billion annually—is smaller than Medicare’s $216 billion.
Industry experts believe this agreement may pressure rivals such as AstraZeneca and Eli Lilly, who have already pledged U.S. manufacturing expansion, to follow suit. While patients in Medicaid stand to benefit, health economists stress that the broader impact would be far greater if similar price cuts extended to Medicare.
By securing tariff relief while offering targeted price cuts, Pfizer and Trump’s administration have crafted a deal that may reshape U.S. drug pricing strategies ahead of TrumpRx’s 2026 launch.
